Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
Last trade$0.8829
Day change-$0.0108 (-1.21%)
Day range$0.883 – $0.906
Volume18,575
Market cap$91M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for NYXH.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for NYXH.
Recent news
Company coverage with links to the original publishers.
Inspire Medical Systems (INSP) shares gained 12.1% over three months despite a 7.9% revenue decline and 62.2% drop in adjusted Q3 EPS. Reimbursement issues cost the company $30M in Q3 revenues with a projected $120M full-year 2026 impact. The company targets low-single-digit revenue growth in 2027 through Project Horizon and battery replacement procedures, though reimbursement execution remains a key risk factor.
Nyxoah SA (NYXH) reported a quarterly loss of $0.2 per share, beating consensus estimates of $0.24 loss, with a 16.67% earnings surprise. However, revenues of $10.55 million missed estimates by 5.02%. The stock has declined 81.3% year-to-date versus the S&P 500's 12.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Tempus AI (TEM) reported quarterly earnings of $0.07 per share, beating consensus estimates of a loss of $0.09, representing a 177.78% earnings surprise. The company posted revenues of $411.54 million, surpassing estimates by 0.05% and showing year-over-year growth from $334.21 million. However, the stock received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. The Medical Info Systems industry ranks in the top 36% of Zacks industries.
Nyxoah reported Q3 2026 global net revenue of €9.2 million with 29% sequential U.S. growth, but lowered full-year 2026 revenue guidance to €33-35 million from €36-40 million. The company submitted a PMA supplement to expand its Genio hypoglossal nerve stimulation system to Complete Concentric Collapse patients, with the ACCCESS study meeting efficacy endpoints at 77.2% AHI responder rate.
Nyxoah reported Q3 2026 net revenue of €9.2 million with 29% sequential growth in US sales. The company submitted a PMA supplement to the FDA to expand Genio's indication to complete concentric collapse patients, with the ACCCESS study meeting primary efficacy endpoints (77.2% responder rate). However, full-year 2026 revenue guidance was lowered to €33-35 million from €36-40 million.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.